Teva Settles Generic Drug Delay Lawsuit for $512M

By on April 20, 2015

Teva Pharmaceutical Industries Ltd  (TEVA) settled a class action lawsuit involving allegations that the company delayed generic versions of Provigil, a drug made by Teva’s Cephalon unit to treat daytime sleepiness associated with obstructive sleep apnea.

The lawsuit claims that Teva and Cephalon violated federal antitrust law by conspiring with Mylan Inc. and Ranbaxy Laboratories Ltd over patent lawsuit settlements to defer the release of Provigil generics until 2012.

Teva settled the case for $512 million, the largest settlement ever involving allegations of delaying generic drugs.

If you would like additional information on the Teva Pharmaceutical settlement or other news, please click the green button below and fill out the form.